Treatment of HIV infection.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin at baseline and with modification of treatment.
Common
Serious
Antimicrobial class: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor
Pregnancy category: B
Average serum half life: 50 hours
Precautions: QT interval prolongation has been reported; use with caution with coadministration of other medications associated with an increased risk of torsade de pointes.
Monitoring recommended with underlying hepatic disease or marked elevations in baseline transaminases; consider monitoring in patients without preexisting hepatic impairment or other risk factors.
Discontinue immediately if signs or symptoms of severe skin and hypersensitivity reactions develop.
Depressive disorders have been reported; evaluate benefit and risk of continued treatment.
항생제
